403 related articles for article (PubMed ID: 23078246)
1. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.
Yang W; Wang L; Roehn G; Pearlstein RD; Ali-Osman F; Pan H; Goldbrunner R; Krantz M; Harms C; Paschen W
Cancer Sci; 2013 Jan; 104(1):70-7. PubMed ID: 23078246
[TBL] [Abstract][Full Text] [Related]
2. Assessing the Role of Paralog-Specific Sumoylation of HDAC1.
Citro S; Chiocca S
Methods Mol Biol; 2017; 1510():329-337. PubMed ID: 27761832
[TBL] [Abstract][Full Text] [Related]
3. Small ubiquitin-like modifier 3-modified proteome regulated by brain ischemia in novel small ubiquitin-like modifier transgenic mice: putative protective proteins/pathways.
Yang W; Sheng H; Thompson JW; Zhao S; Wang L; Miao P; Liu X; Moseley MA; Paschen W
Stroke; 2014 Apr; 45(4):1115-22. PubMed ID: 24569813
[TBL] [Abstract][Full Text] [Related]
4. Effect of endosulfan and bisphenol A on the expression of SUMO and UBC9.
Yarahalli Jayaram V; Baggavalli S; Reddy D; Sistla S; Malempati R
Drug Chem Toxicol; 2020 Nov; 43(6):637-644. PubMed ID: 30426790
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the interactions of HIV-1 integrase with small ubiquitin-like modifiers and their conjugation enzyme Ubc9.
Li Z; Wu S; Wang J; Li W; Lin Y; Ji C; Xue J; Chen J
Int J Mol Med; 2012 Nov; 30(5):1053-60. PubMed ID: 22895527
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies.
Sha Z; Blyszcz T; González-Prieto R; Vertegaal ACO; Goldberg AL
J Biol Chem; 2019 Oct; 294(42):15218-15234. PubMed ID: 31285264
[TBL] [Abstract][Full Text] [Related]
7. E2-mediated small ubiquitin-like modifier (SUMO) modification of thymine DNA glycosylase is efficient but not selective for the enzyme-product complex.
Coey CT; Fitzgerald ME; Maiti A; Reiter KH; Guzzo CM; Matunis MJ; Drohat AC
J Biol Chem; 2014 May; 289(22):15810-9. PubMed ID: 24753249
[TBL] [Abstract][Full Text] [Related]
8. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
9. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A
J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659
[TBL] [Abstract][Full Text] [Related]
10. Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3.
Evdokimov E; Sharma P; Lockett SJ; Lualdi M; Kuehn MR
J Cell Sci; 2008 Dec; 121(Pt 24):4106-13. PubMed ID: 19033381
[TBL] [Abstract][Full Text] [Related]
11. Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model.
McMillan LE; Brown JT; Henley JM; Cimarosti H
Neurosci Lett; 2011 Sep; 502(3):201-8. PubMed ID: 21843595
[TBL] [Abstract][Full Text] [Related]
12. Thyroid hormone receptor isoform-specific modification by small ubiquitin-like modifier (SUMO) modulates thyroid hormone-dependent gene regulation.
Liu YY; Kogai T; Schultz JJ; Mody K; Brent GA
J Biol Chem; 2012 Oct; 287(43):36499-508. PubMed ID: 22930759
[TBL] [Abstract][Full Text] [Related]
13. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs).
Wu YC; Roark AA; Bian XL; Wilson VG
Virology; 2008 Sep; 378(2):329-38. PubMed ID: 18619639
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms and functions of SUMOylation in health and disease: a review focusing on immune cells.
Huang CH; Yang TT; Lin KI
J Biomed Sci; 2024 Jan; 31(1):16. PubMed ID: 38280996
[TBL] [Abstract][Full Text] [Related]
15. A Fluorescent In Vitro Assay to Investigate Paralog-Specific SUMO Conjugation.
Eisenhardt N; Chaugule VK; Pichler A
Methods Mol Biol; 2016; 1475():67-78. PubMed ID: 27631798
[TBL] [Abstract][Full Text] [Related]
16. Identification of a new small ubiquitin-like modifier (SUMO)-interacting motif in the E3 ligase PIASy.
Kaur K; Park H; Pandey N; Azuma Y; De Guzman RN
J Biol Chem; 2017 Jun; 292(24):10230-10238. PubMed ID: 28455449
[TBL] [Abstract][Full Text] [Related]
17. Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation.
Tatham MH; Kim S; Yu B; Jaffray E; Song J; Zheng J; Rodriguez MS; Hay RT; Chen Y
Biochemistry; 2003 Aug; 42(33):9959-69. PubMed ID: 12924945
[TBL] [Abstract][Full Text] [Related]
18. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.
Licciardello MP; Müllner MK; Dürnberger G; Kerzendorfer C; Boidol B; Trefzer C; Sdelci S; Berg T; Penz T; Schuster M; Bock C; Kralovics R; Superti-Furga G; Colinge J; Nijman SM; Kubicek S
Oncogene; 2015 Jul; 34(29):3780-90. PubMed ID: 25263445
[TBL] [Abstract][Full Text] [Related]
19. SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression.
Bellail AC; Olson JJ; Hao C
Nat Commun; 2014 Jun; 5():4234. PubMed ID: 24953629
[TBL] [Abstract][Full Text] [Related]
20. Sumoylation of human argonaute 2 at lysine-402 regulates its stability.
Sahin U; Lapaquette P; Andrieux A; Faure G; Dejean A
PLoS One; 2014; 9(7):e102957. PubMed ID: 25036361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
